Ken Griffin Enlivex Therapeutics Ltd. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.27 - $4.31 $17,526 - $59,477	-13,800 Reduced 80.23%	3,400 $4,000
Q1 2024 May 15, 2024	BUY	$2.54 - $4.3 $43,688 - $73,960	17,200 New	17,200 $65,000
Q3 2023 Nov 14, 2023	SELL	$1.46 - $2.97 $7,884 - $16,038	-5,400 Reduced 52.43%	4,900 $7,000
Q2 2023 Aug 14, 2023	BUY	$2.51 - $3.71 $9,287 - $13,727	3,700 Added 56.06%	10,300 $27,000
Q1 2023 May 15, 2023	SELL	$3.41 - $4.55 $89,683 - $119,665	-26,300 Reduced 79.94%	6,600 $24,000
Q4 2022 Feb 14, 2023	SELL	$3.74 - $4.81 $68,816 - $88,504	-18,400 Reduced 35.87%	32,900 $129,000
Q3 2022 Nov 14, 2022	BUY	$4.11 - $5.87 $210,843 - $301,131	51,300 New	51,300 $218,000

2.1M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23.4M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.